Barclays Maintains Equal-Weight on CRISPR Therapeutics, Lowers Price Target to $59
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Gena Wang maintains an Equal-Weight rating on CRISPR Therapeutics (NASDAQ:CRSP) but lowers the price target from $67 to $59.
August 06, 2024 | 1:32 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Barclays analyst Gena Wang maintains an Equal-Weight rating on CRISPR Therapeutics but lowers the price target from $67 to $59.
The lowered price target from $67 to $59 suggests a less optimistic outlook for CRISPR Therapeutics, which could negatively impact investor sentiment and short-term stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100